Dolutegravir plus rilpivirine: benefits beyond viral suppression

Dolutegravir plus rilpivirine: benefits beyond viral suppression

Abstract. Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the...

Full description

Bibliographic Details
Main Authors: Jesús Troya, MD, PhD, Carlos Dueñas, MD, Idoia Irazola, MD, Ignacio de los Santos, MD, PhD, Sara de la Fuente, MD, PhD, Desiré Gil, MD, PhD, Cristina Hernández, MD, María José Galindo, MD, PhD, Julia Gómez, MD, Elisabeth Delgado, MD, Estela Moreno-García, MD, Guillermo Posada, MD, PhD, Teresa Aldámiz, MD, PhD, Jose Antonio Iribarren, MD, José Manuel Guerra, MD, PhD, Miguel Ángel Morán, MD, Carlos Galera, MD, PhD, Javier Fuente, MD, Ana Peláez, MD, PhD, Miguel Cervero, MD, PhD, María Garcinuño, MD, Marta Montero, MD, Francisco Ceballos, PhD, Luis Buzón, MD, PhD, on behalf of the DORIPEX Study Group∗∗
Format: Article
Language:English
Published: Wolters Kluwer 2022-06-01
Series:Medicine
Online Access:http://journals.lww.com/10.1097/MD.0000000000029252

Internet

http://journals.lww.com/10.1097/MD.0000000000029252

Similar Items